Extension of a 5 year contract

RNS Number : 7886P

IXICO plc

05 September 2017

 

5 September 2017

IXICO plc

("IXICO" or the "Company")

Extension of a 5 year contract in a Phase II/III Alzheimer's Disease clinical trial

with a top 10 global pharmaceutical company

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed an extension and expansion to its largest existing contract, which was awarded in August 2015, for a Phase II/III clinical trial contract in Alzheimer's Disease. Consequently, the total contract value has increased from US$6.8m to US$7.7m, of which US$1.0m has been recognised to date. The contract term has been extended by eight months to May 2024.

In this study IXICO utilises its expertise and proprietary technology platform to collect, measure and monitor changes in disease pathology of participants in the trial. The expansion reflects the addition of additional image data standardisation and collection services, which will be provided over the duration of the study.

Giulio Cerroni, CEO of IXICO, commented

"We are delighted to announce an extension to this significant existing agreement which reflects the opportunities we continue to develop to enhance our privileged position as trusted partners, to provide additional technology enabled services to our pharmaceutical customers".

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield /James Wolfe	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway / Mo Noonan	Tel: [phone]

About IXICO

IXICO is the digital technologies company serving neuroscience.  Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.  Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

 

END

 

 

CNTEAKNLELPXEFF